<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03875859</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-49542</org_study_id>
    <secondary_id>SKIN0050</secondary_id>
    <nct_id>NCT03875859</nct_id>
  </id_info>
  <brief_title>Topical Remetinostat Gel as Neoadjuvant Therapy in Patients With Squamous Cell Carcinoma (SCC)</brief_title>
  <official_title>A Phase 2 Open Label, Single Arm Trial to Investigate the Efficacy and Safety of Topical Remetinostat Gel as Neoadjuvant Therapy in Patients Undergoing Surgical Resection of Squamous Cell Carcinoma (SCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kavita Sarin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivir</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine if 8 weeks of topical remetinostat applied&#xD;
      three times daily will suppress Squamous Cell Carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary purpose of this study is:&#xD;
&#xD;
        -  to determine if 8 weeks of topical remetinostat gel applied 3 times daily (TID) under&#xD;
           occlusion will suppress SCC growth&#xD;
&#xD;
        -  to determine the overall response rate (ORR) of SCCs after 8 weeks of treatment with&#xD;
           topical remetinostat gel 1%, as measured by at least 30% decrease in greatest area (in&#xD;
           mm2).&#xD;
&#xD;
             -  Subjects with at least 1 biopsy-proven cutaneous SCC will be recruited for this&#xD;
                study.&#xD;
&#xD;
             -  Subjects will apply remetinostat gel 1% to at least 1 SCC.&#xD;
&#xD;
             -  Non-invasive cutaneous SCC lesions, including Bowen's disease, are also eligible&#xD;
                for this study&#xD;
&#xD;
             -  There is 1 treatment option: Topical remetinostat gel 1% applied 3 times daily.&#xD;
&#xD;
             -  The study is a single arm, open label design&#xD;
&#xD;
             -  For purposes of ClinicalTrials.gov, there is no secondary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The available study medication reached expiry (logistics).&#xD;
  </why_stopped>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Actual">January 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 14, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response (OR)</measure>
    <time_frame>10 weeks</time_frame>
    <description>Overall response (OR) will be assessed in squamous cell carcinoma (SCC). Objective response (OR) will defined as the number of lesions with either a complete response (CR) or a partial response (PR) among all eligible and treated lesions, any time within 10 weeks.&#xD;
Complete Response (CR) = Disappearance of target lesion&#xD;
Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesion&#xD;
Overall Response (OR) = CR + PR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events Contributing to Treatment Discontinuation or Interruption</measure>
    <time_frame>8 weeks</time_frame>
    <description>Adverse events (AEs) contributing to treatment discontinuation or interruption are reported as the number of such events, a number without dispersion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Discontinued Treatment or Had Treatment Interruption</measure>
    <time_frame>8 weeks</time_frame>
    <description>The number of participants who discontinued treatment or experienced treatment interruption within the first 8 weeks of treatment are reported as the number of such participants, a number without dispersion.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Remetinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remetinostat</intervention_name>
    <description>Topical 1% remetinostat gel</description>
    <arm_group_label>Remetinostat</arm_group_label>
    <other_name>suberohydroxamic acid phenyl ester (SHAPE); SHAPE Gel;</other_name>
    <other_name>SHP-141;</other_name>
    <other_name>and 4-[[8-(hydroxyamino)-1,8-dioxooctyl]oxy]-benzoic acid methyl ester</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have at least one biopsy-proven cutaneous SCC or SCC in situ (SCC-IS) lesion&#xD;
             greater than or equal to 5 mm. Non-invasive SCC lesion(s), including Bowen's disease&#xD;
             (SCC-IS), are eligible, but must be amenable to surgical resection.&#xD;
&#xD;
          2. 18 years of age or older.&#xD;
&#xD;
          3. Must be willing to apply the topical remetinostat 3 times daily for 8 weeks and cover&#xD;
             with an occlusive bandage.&#xD;
&#xD;
          4. Negative serum pregnancy test within 14 days prior to the first dose of study therapy&#xD;
             for women of child-bearing potential, defined as a sexually mature woman who has not&#xD;
             undergone a hysterectomy or who has not been naturally postmenopausal for at least 24&#xD;
             consecutive months (i.e., who has had menses any time in the preceding 24 consecutive&#xD;
             months)&#xD;
&#xD;
          5. Sexually active women of child bearing potential (WCBP) and male patients with a&#xD;
             female partner of child-bearing potential must agree to use acceptable methods of&#xD;
             contraception to avoid pregnancy (for example, oral, injectable, or implantable&#xD;
             hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive&#xD;
             with spermicide; or vasectomized partner) before the first dose of study therapy and&#xD;
             for 3 months after the last dose of study therapy&#xD;
&#xD;
          6. Has signed and dated the current, approved informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any large (&gt; 20 mm) SCC lesion. Patients with large SCC lesion(s) will be referred for&#xD;
             evaluation for surgical resection.&#xD;
&#xD;
          2. Inoperable locally-advanced and/or non-cutaneous metastatic SCC.&#xD;
&#xD;
          3. SCC lesion(s) in cosmetically-sensitive areas (e.g. tip of nose, eyelid) are not&#xD;
             eligible for enrollment. (If a patient has SCC lesion(s) in other areas, those&#xD;
             tumor(s) may be considered for enrollment.)&#xD;
&#xD;
          4. Taking any medication known to affect SCC growth&#xD;
&#xD;
          5. Within the past 6 months, has used topical or systemic therapies that might interfere&#xD;
             with the evaluation of the study medication during the study. Specifically, these&#xD;
             include the topical use at the site of the study tumors:&#xD;
&#xD;
               -  Glucocorticoids&#xD;
&#xD;
               -  Retinoids either systemically or topically at the tumor site (e.g., etretinate,&#xD;
                  isotretinoin, tazarotene, tretinoin, adapalene)&#xD;
&#xD;
               -  Alpha-hydroxy acids (e.g., glycolic acid, lactic acid) to the tumor site&#xD;
&#xD;
               -  5-fluorouracil or imiquimod&#xD;
&#xD;
          6. Has received treatment with systemic chemotherapy within 60 days prior to starting&#xD;
             study medication.&#xD;
&#xD;
          7. Currently receiving systemic medications that could affect SCC tumors (e.g., oral&#xD;
             retinoids) or might interact with remetinostat&#xD;
&#xD;
          8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, recurrent seizure history or psychiatric illness/social situations that&#xD;
             would limit compliance with study requirements.&#xD;
&#xD;
          9. Moderate to significant immunosuppression (e.g., active cancer, significant autoimmune&#xD;
             disease) and/or receiving immunosuppressive drugs that result in moderate to&#xD;
             significant immunosuppression (e.g. low dose oral glucocorticoids do not necessarily&#xD;
             exclude a patient)&#xD;
&#xD;
         10. Known or previous hypersensitivity to HDACi&#xD;
&#xD;
         11. History of congestive heart failure, cardiac arrhythmias, or other findings of&#xD;
             ventricular dysfunction.&#xD;
&#xD;
         12. Pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kavita Y Sarin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <results_first_submitted>April 28, 2021</results_first_submitted>
  <results_first_submitted_qc>April 28, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2021</results_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Kavita Sarin</investigator_full_name>
    <investigator_title>Assistant Professor of Dermatology.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzoic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03875859/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remetinostat</title>
          <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Remetinostat</title>
          <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.5" spread="6.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response (OR)</title>
        <description>Overall response (OR) will be assessed in squamous cell carcinoma (SCC). Objective response (OR) will defined as the number of lesions with either a complete response (CR) or a partial response (PR) among all eligible and treated lesions, any time within 10 weeks.&#xD;
Complete Response (CR) = Disappearance of target lesion&#xD;
Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesion&#xD;
Overall Response (OR) = CR + PR</description>
        <time_frame>10 weeks</time_frame>
        <population>All treated lesions for all participants were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Remetinostat</title>
            <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response (OR)</title>
          <description>Overall response (OR) will be assessed in squamous cell carcinoma (SCC). Objective response (OR) will defined as the number of lesions with either a complete response (CR) or a partial response (PR) among all eligible and treated lesions, any time within 10 weeks.&#xD;
Complete Response (CR) = Disappearance of target lesion&#xD;
Partial Response (PR) = ≥ 30% decrease in the sum of the longest diameter of target lesion&#xD;
Overall Response (OR) = CR + PR</description>
          <population>All treated lesions for all participants were included in the analysis.</population>
          <units>tumor lesions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>OR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events Contributing to Treatment Discontinuation or Interruption</title>
        <description>Adverse events (AEs) contributing to treatment discontinuation or interruption are reported as the number of such events, a number without dispersion.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remetinostat</title>
            <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Contributing to Treatment Discontinuation or Interruption</title>
          <description>Adverse events (AEs) contributing to treatment discontinuation or interruption are reported as the number of such events, a number without dispersion.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Discontinued Treatment or Had Treatment Interruption</title>
        <description>The number of participants who discontinued treatment or experienced treatment interruption within the first 8 weeks of treatment are reported as the number of such participants, a number without dispersion.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remetinostat</title>
            <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Discontinued Treatment or Had Treatment Interruption</title>
          <description>The number of participants who discontinued treatment or experienced treatment interruption within the first 8 weeks of treatment are reported as the number of such participants, a number without dispersion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Remetinostat</title>
          <description>Subjects will apply remetinostat gel 1% to at least 1 SCC: Topical remetinostat gel 1% applied 3 times daily.&#xD;
Remetinostat: Topical 1% remetinostat gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (5.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kavita Yang Sarin</name_or_title>
      <organization>Stanford University</organization>
      <phone>650-804-2899</phone>
      <email>ksarin@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

